BEGIN:VCALENDAR
VERSION:2.0
PRODID:Linklings LLC
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
X-LIC-LOCATION:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:19700308T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:19701101T020000
RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTAMP:20210916T132447Z
LOCATION:Henry Dunant
DTSTART;TZID=Europe/Stockholm:20210705T153000
DTEND;TZID=Europe/Stockholm:20210705T160000
UID:submissions.pasc-conference.org_PASC21_sess121_msa318@linklings.com
SUMMARY:Design and Implementation of In-Silico Trials for Acute Ischemic S
 troke
DESCRIPTION:Minisymposium\n\nDesign and Implementation of In-Silico Trials
  for Acute Ischemic Stroke\n\nHoekstra, Miller, van der Kolk, Padmos\n\nIn
  silico trials are patient-specific simulations on a cohort of virtual pat
 ients to support the development and evaluation of medical devices, drugs 
 and treatment. In silico trials have the potential to refine, reduce cost,
  and partially replace current clinical trials or animal experimentation. 
 We present the design and implementation of an in silico trial for treatme
 nt of acute ischemic stroke, and demonstrate running a trial. The in silic
 o trial is implemented as an event-based simulation for stroke and treatme
 nt, and is designed to be compartmental to aid development and reproducibi
 lity. A statistical population model will be used to generate cohorts of v
 irtual patients. Sophisticated 3D simulations can be replaced by surrogate
  and statistical models such that the framework can be run for large cohor
 ts of patients. Ways to overcome some of the challenges and difficulties i
 n setting up such an in silico trial are discussed.\n\nDomain: CS and Math
 , Chemistry and Materials, Physics, Life Sciences, Engineering
END:VEVENT
END:VCALENDAR